KR20190058127A - Compositions for the prevention or treatment of oral diseases, including extracts of acer tegmentosum maxim extract - Google Patents

Abstract

The present invention relates to a composition for preventing or treating oral diseases, which, by containing Acer tegmentosum as an active component, has an excellent effect for inhibiting proliferation of various pathogenic fungi causing oral diseases to prevent or treat oral diseases. A technical point of the present invention is that the composition contains Acer tegmentosum as the active component.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention or treatment of oral diseases,

The present invention relates to a composition for preventing or treating an oral disease including a saphenous extract, and more particularly, to a composition for preventing or treating an oral disease by inhibiting the proliferation of various pathogens causing oral diseases, And to compositions for preventing or treating oral diseases having excellent effects.

Hyundai is one of the aspirations to live a healthier life. Not only does he want to have healthy teeth even after 80 years of age, but he also rinses his mouth after meals to reduce bad breath that interferes with interpersonal relationships. Oral cleaning is performed for the purpose of preventing oral diseases such as dental caries, halitosis, and periodontitis, which are caused by damage to the oral cavity and teeth caused by changes in the eating habits of modern people.

Oral detergent currently marketed in the market is manufactured by using sodium fluoride, benzethonium chloride, polyoxyethylene, polyoxypropylene polymer, cetylpyridinium chloride, sodium saccharin, and sodium benzoate, which are antibacterial components, . However, when swallowing these ingredients, they show side effects such as vomiting, nervous breakdown, coma, and diarrhea. When they swallow excess, they cause fatal damage and damage to the oral cavity during long-term use.

In particular, antibiotics such as penicillin, erythromycin, and tetracycline are effective for inhibiting sterilization and growth among drugs used for the purpose of preventive treatment of periodontitis. However, side effects such as inducing the appearance of resistant bacteria are large, and antibacterial agents such as chlorhexidine, But it is known to be highly toxic.

Therefore, it is necessary to develop a natural substance which has no side effects from natural products such as medicinal plants, has high antimicrobial activity selectively against harmful oral microorganisms, and has a function of inhibiting substratease.

On the other hand, it is also called as Acer tegmentosum maxim. It is a deciduous broad-leaved arboreous tree with a maple tree, and it is a plant that habitats in the highlands. Traditionally, it has been used as a medicinal substance in the country, and has the efficacy of liver function recovery, No constitution is known to have no side effects.

As described above, various pharmacological effects of Sanchenoides have been reported. However, the effect of preventing or treating oral diseases of the Sancococcus extract has not yet been known, and there has been no research on them.

Accordingly, the present inventor has made efforts to develop a composition capable of exhibiting the preventive or therapeutic effect of oral diseases, containing an effective ingredient derived from a natural product, which has less side effects on the human body than a chemical synthetic medicine and can be easily prepared and ingested. And the present invention has been completed.

KR 10-1641213 B1 KR 10-2016-0050108 A

Disclosure of the Invention The present invention has been conceived to solve the above-mentioned problems. It is an object of the present invention to provide a method for preventing or treating oral diseases, which comprises an effective ingredient derived from a natural product which has less side effects on human body than a chemical synthetic medicine, A composition for prevention or treatment of oral diseases, which comprises an extract of a saphenous tree as an active ingredient.

Meanwhile, the object of the present invention is not limited to the above-mentioned objects, and other objects not mentioned can be clearly understood from the following description.

The present invention relates to a pharmaceutical composition for preventing or treating oral diseases, which comprises an extract of a Chinese cabbage as an active ingredient.

In addition, the above-mentioned extract of the saponin extract may be dissolved in water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, diethyl ether and cyclohexane And is extracted using one or more selected solvents.

In addition, the oral disease is characterized by being selected from the group consisting of bad breath, tooth decay, stomatitis, dental caries, periodontal disease, oral mucosal ulcer and dry mouth syndrome.

In order to solve the above-mentioned technical problems, the present invention relates to a food composition for preventing or ameliorating an oral disease, which comprises an extract of a Chinese cabbage as an active ingredient.

By the means for solving the above problems, the composition for preventing or treating oral diseases according to the present invention is excellent in preventing or treating oral diseases by inhibiting the growth of pathogens causing oral diseases As a natural product, there are few side effects on the human body, and there is an effect that it can be easily prepared and ingested.

FIG. 1 is a graph showing the results of an antioxidative activity evaluation experiment of a Chinese cabbage extract according to an embodiment of the present invention.
FIG. 2 is a photograph showing the results of an antioxidative activity evaluation test of a Chinese cabbage extract according to an embodiment of the present invention. FIG.

BRIEF DESCRIPTION OF THE DRAWINGS The advantages and features of the present invention and the manner of achieving them will become apparent with reference to the embodiments described in detail below with reference to the accompanying drawings. However, the present invention is not limited to the embodiments described below, but may be embodied in various different forms, and these embodiments are not intended to be exhaustive or to limit the scope of the present invention to the precise form disclosed, It is provided to inform the person completely of the scope of the invention. And the terminology used herein is for the purpose of illustrating embodiments and is not intended to be limiting of the present invention. The singular forms herein include plural forms unless the context clearly dictates otherwise.

Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. Brief Description of Drawings FIG. 1 is a block diagram of a computer system according to an embodiment of the present invention; FIG. 2 is a block diagram of a computer system according to an embodiment of the present invention; FIG.

The present invention relates to a composition for the prevention or treatment of oral diseases, which comprises an extract of a saphenous tree as an active ingredient, and the present invention will be described in detail below.

First, the term 'extract' as used herein means that it is used as a crude extract in the art, but it also includes fractions in which the extract is further fractionated. That is, the extracts of the saponins used in the present invention include not only those obtained by using an extraction solvent but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, a separation by various chromatotactypes (made for separation according to size, charge, hydrophobicity or affinity) Fractions obtained through various purification methods are also included in the extract of the present invention. In addition, the extract of the saponin extract used in the present invention can be prepared in powder form by an additional process such as vacuum distillation and freeze-drying or spray-drying.

As used herein, the term "comprising as an active ingredient" means an amount sufficient to achieve the efficacy or activity of the following sapurans extract. Since the present invention is a composition extracted from a natural plant material, Sangchung, there is no adverse effect on the human body even when administered in an excessive amount, so that the quantitative upper limit of the composition of the present invention can be selected by a person skilled in the art within a suitable range.

As used herein, the term ' prophylactic ' means any action that inhibits or slows the progress of oral disease by administration of the composition of the present invention.

In addition, the term " administration " as used herein means providing the desired composition of the present invention to an individual by any suitable method.

The composition for preventing or treating oral diseases according to one embodiment of the present invention contains an extract of Sophora citrifolia as an active ingredient.

The extract of the saponin extract used in the composition of the present invention can be used in water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, Hexane, and the like. Preferably, the solvent may be one obtained by treating saponin to any one solvent selected from the group consisting of water, methanol, ethanol, propanol, isopropanol, butanol, and mixtures thereof, more preferably water, ethanol, Mixture may be used.

In addition, the oral disease is characterized by being selected from the group consisting of bad breath, tooth decay, stomatitis, dental caries, periodontal disease, oral mucosal ulcer and dry mouth syndrome. Preferably, the oral disease may mean tooth decay and periodontal disease.

Periodontal Disease is a chronic, infectious disease (inflammatory disease accompanied by alveolar bone resorption) in which tissue destruction occurs due to host reaction due to deposition of bacterial plaque in periodontal tissue. The cause of periodontal disease can not be explained by one thing but it can be regarded as a chronic disease usually caused by multiple causes.

Several species of pathogenic microorganisms are known to cause cavities and periodontal diseases in the oral cavity. Among them, Streptococcus mutans and Porphyromonas gingivalis are the major pathogens causing tooth decay and periodontal disease [Liliemark WF, Crit. Rev. Oral Bio. Med., 7: 180-198, 1996). Oral pathogenic microorganisms secrete an enzyme called glucosyltransferase (GTase) from the outside of the cells or from the surface to produce glucose and fructose using Sucrose as a substrate in the food, At the same time, insoluble glucan, which is a polymer of glucose, is formed on the tooth surface. Other microorganisms adhere to the formed glucan to form a dental plaque, ie, a dental plaque. Lactic acid bacterium proliferates in this plaque, lactic acid is produced from carbon source with fructose, lactic acid is collected and concentrated in adherent glucan, and the concentrated high concentration acid dissolves Ca ²⁺ in calcium phosphate which is a constituent component of teeth, (Enemel), which is the outer membrane of the tooth, is induced to cause tooth decay [Sigmund, SS, et al., J. Periodontol., 63: 322-331, 1992].

Oral pathogenic microorganisms form plaque, which is a bacterial coat on the tooth surface, and calcium ions (Ca ²⁺ ) of teeth are lost by the accumulation of high concentration of lactic acid produced from lactic acid bacteria that grow in the plaque. This causes tooth decay with the dissolution of tooth enamel enamel, and toxic substances caused by prague penetrate into the crevices between teeth and gums to cause inflammation in the cells, resulting in periodontal diseases such as gingivitis and periodontitis.

Bacterial antigens, such as Endotixin or Lipopolysaccharide (LPS) from plaque enter the gingival tissues, and the neutrophils and macrophages thus induced are activated by the digestion of the bacterial antigens from the plaque, Enzymes such as collagenase, gelatinase, elastin hydrolytic enzyme and cathepsin G are released to the outside of the cell. These enzymes work together to decompose the organic components of gingival tissue, such as collagen and proteoglycans.

On the other hand, neutrophils or macrophages release inflammatory cytokines and stimulate the production of matrix metalloproteinases (MMPs) by stimulating surrounding gingival fibroblasts, but TIMF (Tissue), an inhibitor of these enzymes inhibitor of metalloprotease) production is almost unchanged or rather suppressed so that the substrate (collagen) is degraded. Therefore, softening and breakdown of the gingival tissue and continuous bleeding occur. As an important supplier of enzymes involved in collagen degradation, periodontal disease-causing bacteria such as Porphyromonas gingivalis, which is distributed in prags, can be mentioned. These bacteria secrete proteolytic enzymes similar to collagen hydrolase and trypsin, which break down the connective tissue such as collagen and fibronectin.

Bacterial enzymes also exhibit MMP activity by activating inactive precursors or degrading TIMF. Proteoglycans in periodontal tissues can be degraded by various bacterial enzymes and macromolecules such as collagen, proteoglycan and hyarulonic acid are destroyed by normal cellular metabolites such as free radicals.

According to one embodiment of the present invention, the extract of the saponin is selected from the group consisting of Streptococcus mutans, Staphylococcus aureus, Porphyromonas ginivalis, Agregatia vector actinomycin, As a result of confirming the growth inhibitory activity of Actinobacillus actinomycetemcomitans, it is considered that the extract of Sanchenian oak extract is effective in preventing or treating oral diseases by inhibiting the growth of pathogenic microorganisms causing oral diseases.

The composition according to one embodiment of the present invention may be prepared by any one or more formulations selected from the group consisting of dentifrices, chewing gum, oral cleanser, oral cleanser, oral spray, oral ointment and oral patch Can be used.

The dentifrice of the present invention includes a composition selected from the group consisting of an abrasive, a binder, a moisturizer, an active ingredient, a foaming agent, a sweetener, and a flavoring agent.

Examples of the polishing agent include aluminum hydroxide, silicic anhydride, aluminum silicate, calcium secondary phosphate, secondary hydroxide and anhydride, calcium tertiary phosphate, calcium carbonate, calcium pyrophosphate, insoluble sodium metaphosphate, magnesium phosphate, magnesium carbonate, Polymethyl methacrylate, other synthetic resins, etc., in an amount of about 10-90% of the total composition.

Examples of the binder include carrageenan, various incremental cellulose derivatives, zeolite such as xanthan gum and tragacanth gum, synthetic polymers such as polyvinyl alcohol, sodium polyacrylate, polyacrylic acid / maleic acid copolymer, and carboxyvinyl polymer Derivatives and the like, and in inorganic binders such as silica and laponite, they may be used alone or in combination of two or more.

Meanwhile, compositions according to one embodiment of the present invention include Mentol, Anetol, Eugenol, Limonene, Ocimene, n-Dodecyl Alcohol, Citronenol, a-Terpineol, Methyl salycilate, Methyl Acetate, Citronelyl Acetate, Cineol, Linalool, Ethyl Linalool, Vanillin, Thymol, Speamint Oil, Sage Oil, Rosemary Oil, Cinamon Oil and the like. The dyes may be used alone or in combination in an amount of 0.1 to 10%, preferably 0.5 to 5%, of the total composition.

In addition, sweetening agents such as sodium saccharin, stevioside, aspartame, D-xylose and the like may be used in combination.

The oral compositions of the present invention include cationic disinfectants such as triclosan, chlorohexidine, benzethonium chloride, benzalkonium chloride, cetylpyridium chloride, alkali metal monofluorophosphates such as sodium monophosphate and potassium monophosphate, And fluoride such as sodium fluoride and tin fluoride, organic acids such as tranexamic acid, epsilon aminocaproic acid, aluminum chlorohydroxide allantoin, dihydrocholestanol, clitilipinic acid, glycerophosphate, sodium chloride, It is possible to use one or more kinds of effective ingredients such as ascorbic acid (sodium), dl-a-tocopherol acetate, xylitol, pyridoxine hydrochloride, and polyvinylpyrrolidone.

In addition, anionic surfactants, nonionic surfactants, and / or amphoteric surfactants can be used as the surfactant used as a foaming component in the oral composition of the present invention. Examples of the anionic surfactant include sodium alkylsulfate such as sodium laurylsulfate and sodium myristylsulfate, sodium N-Lauroyl sarcosinate, sodium N-miristyl sarcosinate, etc. Sodium N-acyl sarcosinate and the like can be used. Nonionic surfactants include saccharide-derived fatty acid esters such as sugar fatty acid esters, maltose fatty acid esters and lactose fatty acid esters, poly Oxyethylene hardened castor oil, polyoxyethylene higher alcohol ether, polyoxyethylene polyoxypropylene copolymer, polyoxyethylene polypropylene fatty acid ester, and the like. Examples of the amphoteric surfactant include N-alkyldiaminoethylglycine such as N-lauryldiaminoethylglycine and N-myristyldiaminoethylglycine, N-alkyl-N-carboxymethylammonium betaine, 2- -Hydroxyethyl imidazoline betaine sodium and the like can be used. In this case, anionic surfactant is mainly used as a foaming component, and sodium alkylsulfate such as sodium lauryl sulfate is the most widely used. These surfactants may be used alone or in admixture of two or more, and the blending amount thereof is usually 0.01-0.5%, more preferably 0.05-0.3% of the total composition.

On the other hand, in the preparation of the pharmaceutical composition of the present invention, (a) a pharmaceutically effective amount of the above-mentioned extract of the extract of the present invention; And (b) a pharmaceutically acceptable carrier. In another embodiment, there is provided a pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the above-described extract of the present invention; And (b) a pharmaceutically acceptable carrier. The term " pharmaceutically effective amount " means an amount sufficient to achieve efficacy or activity of the abovementioned sunflower extract.

The pharmaceutically acceptable carrier may be a conventional carrier such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, But are not limited to, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

In addition, the pharmaceutical composition of the present invention can be administered orally or parenterally. The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on such factors as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . Typical dosages of the pharmaceutical compositions of the present invention are in the range of 0.001 to 100 mg / kg on an adult basis.

The pharmaceutical composition of the present invention may be formulated using pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs Or may be manufactured by inserting it into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oil or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or safening agents.

Further, as another embodiment of the present invention, the present invention relates to a food composition for preventing or ameliorating an oral disease comprising an extract of a Chinese cabbage as an active ingredient.

Herein, the food composition for preventing or ameliorating the oral disease includes a saponin extract as an active ingredient as well as a pharmaceutical composition for the prevention or treatment of the above-mentioned oral diseases. The description of the extract is the same as or similar to that described in the above pharmaceutical composition.

The food composition means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be directly eaten through a certain degree of processing, and as a general meaning, , Beverages, food additives, and beverage additives.

Specifically, the food composition may contain, as an active ingredient, not only an extract of saphenous extract, but also a component which is ordinarily added during the production of a food. For example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.

In addition, when the food composition of the present invention is prepared with a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, have.

EXAMPLES Hereinafter, the present invention will be described in detail with reference to Examples. However, the scope of the present invention is not limited to the following Examples.

<Examples>

EXAMPLES Example 1:

The sachet was pulverized using a pulverizer, lyophilized at -20 ° C, 100 g of dried citric acid and 1 L of 80% ethanol were added to the mixer and extracted at room temperature for 4 hours. After the extraction, the filter cake was used to remove the powder components, and only the liquid component was filtered through the flask.

Thereafter, ethanol was added to extract the saponin, so that the filtered liquid component was boiled in a water bath at 65 ° C to prepare a pure saponin extract.

Comparative Example 1: Preparation of an extract of saninari seeds

The extract was prepared in the same manner as in the above Example except that the extract was used.

Comparative Example 2: Preparation of Echinacea extract

The extracts were prepared in the same manner as in the above example except that the extract was used.

<Experimental Example>

Experimental Example 1: Antioxidant activity evaluation experiment

To evaluate the antioxidant activity, DPPH (1,1-diphenyl-2-picryl hydrazyl) radical scavenging activity was measured by removing free radicals and measuring antioxidant activity.

In this experiment, the hydrazyl of DPPH contains an unstable nitrogen atom and can easily accept hydrogen atoms. Therefore, it uses a property of reacting with an antioxidative substance and losing its inherent colorability by accepting hydrogen atoms.

The degree of decrease of radicals using DPPH was measured by a spectrophotometer indirectly, and the antioxidative activity of the sample was measured. When the radicals were reduced to antioxidants, they lost their original purple color and turned yellow.

Specifically, 0.08 g of DPPH and 1 L of ethanol were mixed in a dark room to prepare a DPPH solution. The prepared DPPH solution was stored at -20 ° C.

Then, samples for antioxidant activity evaluation were prepared by concentration. (DPPH solution) was added to 1 ml (control: 99.5% ethanol) of a solution prepared by extracting the saponin extracts at six concentrations of 1000 μg / ml, 500 μg / ml, 250 μg / ml, 125 μg / ml, 62.5 μg / ml and 31.25 μg / After shaking for 10 seconds using a vortex mixer, samples were prepared by concentration at 37 ° C for 30 minutes.

As a positive control, L-ascorbic acid was prepared at 6 concentrations as in the above samples, and 1 ml of DPPH solution was added to prepare a control solution.

The absorbance at 517 nm was measured using an x-Mark micro spectrophotometer reader. The antioxidative activity of the extracts of ascorbic acid and the positive control was determined as abs (control) in the control group (untreated group) Assuming the absorbance as abs (sample), the activity inhibition rate of DPPH was determined according to the following equation, and it is shown in Fig.

Inhibition (%) = abs (control) - abs (sample) / abs (control) * 100

FIG. 1 is a graph showing the results of an antioxidative activity evaluation experiment of a Chinese cabbage extract according to an embodiment of the present invention.

1, the antioxidative activity of L-ascorbic acid, a positive control drug, was 94.59% at a concentration of 1000 μg / ml, 92.31% at a concentration of 500 μg / ml, and 91.74 μg / ml at a concentration of 250 μg / ml , 90.60% at 125 / / ml, 88.32% at 62.5 / / ml, and 86.04% at 31.25 / / ml.

The antioxidant activity of the extracts of the extracts according to the examples was 90.88% at a concentration of 1000 μg / ml, 87.18% at a concentration of 500 μg / ml, 69.23% at a concentration of 250 μg / ml, 36.47% , 13.11% at 62.5 / / ml and 7.47% at 31.25 / / ml.

FIG. 2 is a photograph showing the result of an antioxidative activity evaluation test of a saphenous extract according to an embodiment of the present invention, wherein (a) shows a concentration of 1000 μg / ml, (b) (d) was 125 μg / ml, (e) was 62.5 μg / ml, and (f) was 31.25 μg / ml.

Referring to FIG. 2, it can be seen that DPPH reacts with the extract of saprophyte to lose its intrinsic purple color and turn yellow as the concentration of the saponin extract increases.

That is, as shown in the results of the DPPH radical scavenging activity test shown in FIGS. 1 and 2, the extract of the saponin extract showed antioxidative activity in a concentration-dependent manner and showed activity of about 70% at 250 μg / ml. .

Experimental Example 2: Evaluation test of antibacterial activity

Minimal inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were measured to evaluate the antimicrobial activity against the oral disease pathogens of the extracts of Examples, Comparative Examples 1 and 2.

At this time, the minimum inhibitory concentration (MIC) is the most basic indicator for measuring the antimicrobial activity of the antimicrobial agent. The minimum inhibitory concentration (MIC) is the minimum concentration of the antimicrobial agent that inhibits the growth of bacteria in the in vitro bacterial susceptibility test. Is high.

The minimum bactericidal concentration (MBC) refers to the lowest concentration of the antibacterial agent that reduces the bacteria by at least 99.9%. Most of the antibacterial agents have MIC and MBC because they kill more than 99.9% of the bacteria by the MIC concentration.

Four kinds of pathogenic bacteria causing oral diseases used in this experiment were supplied from Korea Biotechnology Research Institute and Escherichia coli was used as a health indicator microorganism. The types of standard strains used are shown in Table 1 below.

Bacteria strain
Oral diseases
Pathogen Streptococcus mutans GS-5 Staphylococcus aureus ATCC 29213 Porphyromonas ginivalis ATCC 33277 Actinobacillus actinomycetemcomitans ATCC 43747 Indicator fungus Escherichia coli ATCC 25922

The pathogens and surface bacteria shown in Table 1 were sterilized at 121 ° C for 15 minutes in Brain heart infusion (BHI: Difco, Detroit, USA) and incubated at 37 ° C in a 5% CO ₂ incubator. Anaerobic bacteria were maintained in Anaerobic chambers under anaerobic conditions.

(1) Minimal inhibitory concentration (MIC) measurement

The antimicrobial activity against the natural products of Examples, Comparative Examples 1 and 2 was measured by the broth dilution method, and 200 mg / ml of dimethyl sulfoxide (DMSO) was used as a stock solution.

The lowest concentration was determined at 0.04 mg / ml at the highest concentration of 20 mg / ml, and the concentration at the point of time when the growth of the microorganism was inhibited and showed no turbidity was determined as MIC. The results are shown in Table 2 below .

MIC (mg / ml) Comparative Example 1 Comparative Example 2 Example S. mutans - - 2.5 S. aureus - - 2.5 P. ginivalis - - 2.5 A. actinomycetemcomitans - - 5 E. coli - - 10

As shown in Table 2, MICs of 5 kinds of standard strains including oral pathogens and health indicator bacteria were examined. The extracts of the extracts according to the examples showed antimicrobial effect against all strains. The MIC for S. aureus strains and P. ginivalis strains was 2.5 mg / ml, the MIC for A. actinomycetemcomitans strains was 5 mg / ml, and the MIC for E. coli strains was 10 mg / ml .

On the other hand, in the case of the extracts of Comparative Example 1 and Comparative Example 2, the growth of the microorganisms was inhibited and the state of no turbidity could not be observed, which means that the microorganisms did not exhibit an antibacterial effect against all the strains.

(2) Minimal bactericidal concentration (MBC) measurement

10 μl of the culture solution corresponding to the MIC concentration or higher of the natural products according to the Examples, Comparative Examples 1 and 2 was applied to a solid medium and cultured in an anaerobic chamber and a CO ₂ incubator at 37 ° C for 24 hours. The concentration at which the 99.9% of the initial strain was killed was determined by MBC, and the results are shown in Tables 3 to 7 below. In this case, the inhibition of growth (+) means that the growth of the microorganism is not inhibited, and the case of (-) means that the growth of the microorganism is inhibited.

Concentrations inhibition of growth (mg / ml) Inhibition of growth
(S. mutans) Comparative Example 1 Comparative Example 2 Example 20.00 + + - 10.00 + + - 5.00 + + - 2.50 + + - 1.25 + + + 0.63 + + + 0.31 + + + 0.16 + + + 0.08 + + + 0.04 + + +

As shown in Table 3, the results of measurement of MBC for S. mutans strain, which is an oral disease pathogen, indicate that the growth of the strain is effectively inhibited at a concentration of at least 2.50 mg / ml or more .

On the other hand, in the case of the extracts of Comparative Example 1 and Comparative Example 2, it was impossible to observe the time when the S. mutans strain, which is an oral disease pathogen, was killed, indicating that it does not exhibit an antibacterial effect against the strain.

Concentrations inhibition of growth (mg / ml) Inhibition of growth
(S. aureus) Comparative Example 1 Comparative Example 2 Example 20.00 + + - 10.00 + + - 5.00 + + - 2.50 + + - 1.25 + + + 0.63 + + + 0.31 + + + 0.16 + + + 0.08 + + + 0.04 + + +

As shown in Table 4, the results of measurement of MBC of S. aureus strain, which is an oral disease pathogen, indicate that the concentration of at least 2.50 mg / ml of the saponin extract according to the present invention effectively inhibited the growth of the strain .

On the other hand, in the case of the extracts of Comparative Example 1 and Comparative Example 2, it was not observed when the S. aureus strain, which is an oral disease pathogen, was killed, indicating that the strain did not exhibit an antibacterial effect against the strain.

Concentrations inhibition of growth (mg / ml) Inhibition of growth
(P. ginivalis) Comparative Example 1 Comparative Example 2 Example 20.00 + + - 10.00 + + - 5.00 + + - 2.50 + + - 1.25 + + + 0.63 + + + 0.31 + + + 0.16 + + + 0.08 + + + 0.04 + + +

As shown in Table 5, when the MBC of P. ginivalis strain, which is an oral disease pathogen, was examined, it was confirmed that the concentration of the extract of the extracts of the extracts according to the present invention was effectively inhibited at a concentration of at least 2.50 mg / ml .

On the other hand, in the case of the extracts of Comparative Example 1 and Comparative Example 2, it was not observed when the P. ginivalis strain, which is an oral disease pathogen, was killed, which means that it does not exhibit an antimicrobial effect against the strain.

Concentrations inhibition of growth (mg / ml) Inhibition of growth
(A. actinomycetemcomitans) Comparative Example 1 Comparative Example 2 Example 20.00 + + - 10.00 + + - 5.00 + + - 2.50 + + + 1.25 + + + 0.63 + + + 0.31 + + + 0.16 + + + 0.08 + + + 0.04 + + +

As shown in Table 6, MBC of A. actinomycetemcomitans, an oral disease pathogen, was found to be effectively inhibited at a concentration of at least 5.00 mg / ml at a concentration of at least 5.00 mg / ml .

On the other hand, in the case of the extracts of Comparative Example 1 and Comparative Example 2, it was not observed when the A. actinomycetemcomitans strain, which is an oral disease pathogen, was killed, indicating that the extract did not exhibit an antibacterial effect against the strain.

Concentrations inhibition of growth (mg / ml) Inhibition of growth
(E. coli) Comparative Example 1 Comparative Example 2 Example 20.00 + + - 10.00 + + - 5.00 + + + 2.50 + + + 1.25 + + + 0.63 + + + 0.31 + + + 0.16 + + + 0.08 + + + 0.04 + + +

As shown in Table 7, the MBC of the E. coli strains showing health index was effectively inhibited at a concentration of 10.00 mg / ml or more at a concentration of at least 10.00 mg / ml .

On the other hand, in the case of the extracts of Comparative Example 1 and Comparative Example 2, it was not possible to observe the time at which the E. coli strain, which is a health indicator bacterium, was killed, which means that the extract does not exhibit an antibacterial effect against the strain.

As described above, in this Example, the antioxidant activity was analyzed by DPPH radical scavenging activity against the extract of the saponin extract, and the minimum inhibitory concentration (MIC) and the minimum sterilization concentration (MBC) The effectiveness of prevention or treatment was evaluated. As a result, the extract of Sanchenobus chinensis showed an antioxidative activity of about 70% at a concentration of 250 μg / ml, and the antimicrobial activity of the extract also effectively inhibited the growth of pathogenic bacteria causing oral diseases at a concentration of at least 2.5 mg / ml. Respectively. These results suggest that the extract of Aspergillus oryzae has inhibitory effects on growth and proliferation of various pathogenic microorganisms causing oral diseases, and has a preventive or therapeutic effect according to oral diseases.

Therefore, it can be concluded from the results of these Examples that the extract of the present invention has an excellent effect in preventing or treating oral diseases by inhibiting growth of oral pathogens and antioxidant function.

The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the claims of the invention to be described below may be better understood. It will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. The scope of the present invention is defined by the appended claims rather than the foregoing detailed description, and all changes or modifications derived from the appended claims and their equivalents should be construed as being included within the scope of the present invention.

Claims (4)

A composition for preventing or treating an oral disease comprising an extract of a saphenous tree as an active ingredient. The method according to claim 1,
Wherein the extract is selected from the group consisting of water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, diethyl ether and cyclohexane The composition for prevention or treatment of oral diseases is characterized in that it is extracted using at least one solvent. The method according to claim 1,
Wherein the oral disease is selected from the group consisting of bad breath, tooth decay, stomatitis, dental caries, periodontal disease, oral mucosal ulcer, and dry mouth syndrome. A food composition for preventing or ameliorating an oral disease comprising an extract of a saphenous tree as an active ingredient.

Images